Published in Medical Device Business Week, February 24th, 2010
"We tested whether spermine and spermidine could improve the prognostic ability of several established predictors of cancer specific mortality after partial or radical nephrectomy for renal cell carcinoma. Testing was performed on 399 patients with stages T1-4, N0-2, M0-1 renal cell carcinoma who were treated with radical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week